{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T18:48:13Z","timestamp":1789670893438,"version":"4.0.1"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007366","name":"Italian Multiple Sclerosis Foundation","doi-asserted-by":"publisher","award":["2020\/S\/5"],"award-info":[{"award-number":["2020\/S\/5"]}],"id":[{"id":"10.13039\/100007366","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RF-2013-02357497"],"award-info":[{"award-number":["RF-2013-02357497"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014805","name":"Roche SpA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014805","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.msard.2024.105748","type":"journal-article","created":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T18:47:22Z","timestamp":1719686842000},"page":"105748","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Prevalence of elevated sNFL in a real-world setting: Results on 908 patients with different multiple sclerosis types and treatment conditions"],"prefix":"10.1016","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8999-1952","authenticated-orcid":false,"given":"Cecilia Irene","family":"Bava","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Valentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Malucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rugiada","family":"Bottero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Martire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia Di","family":"Sapio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Bertolotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2024.105748_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/NXI.0000000000000555","article-title":"Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS","volume":"6","author":"Akg\u00fcn","year":"2019","journal-title":"Neurol. Neuroimmunol. NeuroInflammation"},{"key":"10.1016\/j.msard.2024.105748_bib0002","unstructured":"ASCLEPIOS-I, n.d. Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis (ASCLEPIOS I) [WWW Document]. 2016. URL https:\/\/clinicaltrials.gov\/study\/NCT02792218."},{"key":"10.1016\/j.msard.2024.105748_bib0003","series-title":"Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis","year":"2016"},{"key":"10.1016\/j.msard.2024.105748_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104662","article-title":"Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials","volume":"93","author":"Bar-Or","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.msard.2024.105748_bib0005","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1474-4422(22)00009-6","article-title":"Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study","volume":"21","author":"Benkert","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2024.105748_bib0006","first-page":"1","article-title":"Factors influencing daily treatment choices in multiple sclerosis: practice guidelines, biomarkers and burden of disease. Ther","volume":"13","author":"Berger","year":"2020","journal-title":"Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2024.105748_bib0007","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1093\/brain\/awab241","article-title":"The potential of serum neurofilament as biomarker for multiple sclerosis","volume":"144","author":"Bittner","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.msard.2024.105748_bib0008","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2217\/nmt-2018-0023","article-title":"Physician and patient treatment decision-making in relapsing-remitting multiple sclerosis in Europe and the USA","volume":"8","author":"Brown","year":"2018","journal-title":"Neurodegener. Dis. Manag."},{"key":"10.1016\/j.msard.2024.105748_bib0009","unstructured":"CARE-MS-I, n.d. Comparison of Alemtuzumab and Rebif\u00ae Efficacy in Multiple Sclerosis, Study One (CARE-MS I) [WWW Document]. 2007. URL https:\/\/clinicaltrials.gov\/study\/NCT00530348."},{"key":"10.1016\/j.msard.2024.105748_bib0010","unstructured":"CARE-MS-II, n.d. Comparison of Alemtuzumab and Rebif\u00ae Efficacy in Multiple Sclerosis, Study Two (CARE-MS II) [WWW Document]. 2007. URL https:\/\/clinicaltrials.gov\/study\/NCT00548405."},{"key":"10.1016\/j.msard.2024.105748_bib0011","doi-asserted-by":"crossref","first-page":"e1201","DOI":"10.1212\/WNL.0000000000009097","article-title":"Blood neurofilament light levels segregate treatment effects in multiple sclerosis","volume":"94","author":"Delcoigne","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2024.105748_bib0012","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ana.24954","article-title":"Serum Neurofilament light: a biomarker of neuronal damage in multiple sclerosis","volume":"81","author":"Disanto","year":"2017","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2024.105748_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnins.2021.642384","article-title":"The evolution of neurofilament light chain in multiple sclerosis","volume":"15","author":"Ferreira-Atuesta","year":"2021","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.msard.2024.105748_bib0014","article-title":"Proportion and characteristics of secondary progressive multiple sclerosis in five European registries using objective classifiers","volume":"9","author":"Forsberg","year":"2023","journal-title":"Mult. Scler. J. - Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2024.105748_bib0015","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s40263-022-00965-7","article-title":"High-efficacy therapies for treatment-na\u00efve individuals with relapsing\u2013remitting multiple sclerosis","volume":"36","author":"Freeman","year":"2022","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2024.105748_bib0016","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/WCO.0000000000000561","article-title":"Disease-modifying treatments for early and advanced multiple sclerosis: a new treatment paradigm","volume":"31","author":"Giovannoni","year":"2018","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.msard.2024.105748_bib0017","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.msard.2015.04.006","article-title":"Is it time to target no evident disease activity (NEDA) in multiple sclerosis?","volume":"4","author":"Giovannoni","year":"2015","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.105748_bib0018","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jamaneurol.2017.4011","article-title":"Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis","volume":"75","author":"Granqvist","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2024.105748_bib0019","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1001\/jamaneurol.2022.4156","article-title":"Time to change the current clinical classification of multiple sclerosis?","volume":"80","author":"Granziera","year":"2023","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2024.105748_bib0020","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1212\/CON.0000000000000738","article-title":"Monitoring, switching, and stopping multiple sclerosis disease-modifying therapies","volume":"25","author":"Gross","year":"2019","journal-title":"Contin. Lifelong Learn. Neurol."},{"key":"10.1016\/j.msard.2024.105748_bib0021","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1001\/jamaneurol.2018.4905","article-title":"Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis","volume":"76","author":"Harding","year":"2019","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2024.105748_bib0022","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/00365513.2020.1730434","article-title":"Reference interval and preanalytical properties of serum neurofilament light chain in Scandinavian adults","volume":"80","author":"Hviid","year":"2020","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"10.1016\/j.msard.2024.105748_bib0023","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1177\/1352458519840757","article-title":"Longitudinal analysis of serum neurofilament light chain: a potential therapeutic monitoring biomarker for multiple sclerosis","volume":"26","author":"Hyun","year":"2020","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2024.105748_bib0024","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1177\/13524585221114007","article-title":"Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: a study from the Italian MS Register","volume":"28","author":"Iaffaldano","year":"2022","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2024.105748_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/cshperspect.a032029","article-title":"Alemtuzumab as treatment for multiple sclerosis","volume":"8","author":"Katsavos","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.msard.2024.105748_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2022.912005","article-title":"Multidimensional overview of neurofilament light chain contribution to comprehensively understanding multiple sclerosis","volume":"13","author":"K\u00f6lliker Frers","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2024.105748_bib0027","doi-asserted-by":"crossref","first-page":"E1007","DOI":"10.1212\/WNL.0000000000007032","article-title":"Blood neurofilament light chain as a biomarker of MS disease activity and treatment response","volume":"92","author":"Kuhle","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2024.105748_bib0028","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1474-4422(22)00289-7","article-title":"Multiple sclerosis progression: time for a new mechanism-driven framework","volume":"22","author":"Kuhlmann","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2024.105748_bib0029","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/j.jalz.2018.06.783","article-title":"Comparison of two platforms quantitating Fg\/Ml neurological biomarkers using single molecule arrays and digital elisa: the benchtop reader Sr-X\u2122 and the fully automated analyzer Hd-1\u2122","volume":"14","author":"Lambert","year":"2018","journal-title":"Alzheimer's Dement"},{"key":"10.1016\/j.msard.2024.105748_bib0030","doi-asserted-by":"crossref","first-page":"E2120","DOI":"10.1212\/WNL.0000000000200258","article-title":"Blood neurofilament light in progressive multiple sclerosis: post hoc analysis of 2 randomized controlled trials","volume":"98","author":"Leppert","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2024.105748_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104762","article-title":"Alemtuzumab treatment in real clinical practice: experience in a multicenter cohort","volume":"75","author":"L\u00f3pez-Real","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.105748_bib0032","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1093\/brain\/aww173","article-title":"Defining secondary progressive multiple sclerosis","volume":"139","author":"Lorscheider","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.msard.2024.105748_bib0033","doi-asserted-by":"crossref","first-page":"E543","DOI":"10.1212\/WNL.0000000000012326","article-title":"Chronic white matter inflammation and serum neurofilament levels in multiple sclerosis","volume":"97","author":"Maggi","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2024.105748_bib0034","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/acn3.50972","article-title":"Confounding effect of blood volume and body mass index on blood neurofilament light chain levels","volume":"7","author":"Manouchehrinia","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.msard.2024.105748_bib0035","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1016\/j.pec.2020.05.014","article-title":"Impact of communication on first treatment decisions in people with relapsing-remitting multiple sclerosis","volume":"103","author":"Manzano","year":"2020","journal-title":"Patient Educ. Couns."},{"key":"10.1016\/j.msard.2024.105748_bib0036","first-page":"43","article-title":"BB-CRESM: a structured institutional biobank for quality research in multiple sclerosis","volume":"26","author":"Marnetto","year":"2020","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2024.105748_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103927","article-title":"Detecting ongoing disease activity in mildly affected multiple sclerosis patients under first-line therapies","volume":"63","author":"Masanneck","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.105748_bib0038","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/jamaneurol.2022.5250","article-title":"Serum glial fibrillary acidic protein compared with neurofilament light chain as a biomarker for disease progression in multiple sclerosis","volume":"80","author":"Meier","year":"2023","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2024.105748_bib0039","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2217\/nmt-2021-0014","article-title":"An updated review of teriflunomide's use in multiple sclerosis","volume":"11","author":"Miller","year":"2021","journal-title":"Neurodegener. Dis. Manag."},{"key":"10.1016\/j.msard.2024.105748_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0274565","article-title":"Neurofilament light chain in blood as a diagnostic and predictive biomarker for multiple sclerosis: a systematic review and meta-analysis","volume":"17","author":"Ning","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.msard.2024.105748_bib0041","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1212\/WNL.0000000000004683","article-title":"Monitoring disease activity in multiple sclerosis using serum neurofilament light protein","volume":"89","author":"Novakova","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2024.105748_bib0042","unstructured":"OPERA-I, n.d. A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis (OPERA I) [WWW Document]. 2011. URL https:\/\/clinicaltrials.gov\/study\/NCT01412333."},{"key":"10.1016\/j.msard.2024.105748_bib0043","unstructured":"OPERA-II, n.d. A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis (OPERA II) [WWW Document]. 2011. URL https:\/\/clinicaltrials.gov\/study\/NCT01247324."},{"key":"10.1016\/j.msard.2024.105748_bib0044","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1136\/jnnp-2020-325304","article-title":"Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab","volume":"92","author":"Pfeuffer","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2024.105748_bib0045","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1177\/1352458517715132","article-title":"Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod","volume":"24","author":"Piehl","year":"2018","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2024.105748_bib0046","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1080\/14737175.2020.1760846","article-title":"Current state-of-art of the application of serum neurofilaments in multiple sclerosis diagnosis and monitoring","volume":"20","author":"Preziosa","year":"2020","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.msard.2024.105748_bib0047","unstructured":"RIFUND-MS, n.d. RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis. (RIFUND-MS) [WWW Document]. 2016. URL https:\/\/clinicaltrials.gov\/study\/NCT02746744."},{"key":"10.1016\/j.msard.2024.105748_bib0048","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/ene.15121","article-title":"A real-world study of alemtuzumab in a cohort of Italian patients","volume":"29","author":"Russo","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2024.105748_bib0049","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1177\/1352458518790390","article-title":"Determinants of therapy switch in multiple sclerosis treatment-na\u00efve patients: a real-life study","volume":"25","author":"Sacc\u00e0","year":"2019","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2024.105748_bib0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/NXI.0000000000000926","article-title":"High serum neurofilament associates with diffuse white matter damage in MS","volume":"8","author":"Saraste","year":"2021","journal-title":"Neurol. Neuroimmunol. neuroinflammation"},{"key":"10.1016\/j.msard.2024.105748_bib0051","first-page":"1324","article-title":"Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment na\u00efve relapsing MS patients","volume":"90","author":"Sejbaek","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2024.105748_bib0052","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1007\/s00415-022-11507-y","article-title":"Validity of serum neurofilament light chain as a prognostic biomarker of disease activity in multiple sclerosis","volume":"270","author":"Sen","year":"2023","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2024.105748_bib0053","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000878","article-title":"Cladribine vs other drugs in MS: merging randomized trial with real-life data","volume":"7","author":"Signori","year":"2020","journal-title":"Neurol. Neuroimmunol. neuroinflammation"},{"key":"10.1016\/j.msard.2024.105748_bib0054","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2147\/PPA.S297052","article-title":"A study comparing patient and clinician perspectives of treatments for multiple sclerosis via group concept mapping","volume":"15","author":"Singer","year":"2021","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.msard.2024.105748_bib0055","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/acn3.51704","article-title":"Associations of sNfL with clinico-radiological measures in a large MS population","volume":"10","author":"Sotirchos","year":"2023","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.msard.2024.105748_bib0056","unstructured":"TENERE, n.d. A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis (TENERE) [WWW Document]. 2009. URL https:\/\/clinicaltrials.gov\/study\/NCT00883337."},{"key":"10.1016\/j.msard.2024.105748_bib0057","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/1352458509356368","article-title":"Short commentary on ?a consensus protocol for the standardization of cerebrospinal fluid collection and biobanking?","volume":"16","author":"Teunissen","year":"2010","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2024.105748_bib0058","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/biomedicines8110523","article-title":"Blood neurofilament light chain: the neurologist's troponin?","volume":"8","author":"Thebault","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.msard.2024.105748_bib0059","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2024.105748_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103090","article-title":"Serum neurofilament light chain levels in healthy individuals: a proposal of cut-off values for use in multiple sclerosis clinical practice","volume":"54","author":"Valentino","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.105748_bib0061","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fneur.2019.00338","article-title":"Neurofilament light chain as a biomarker in multiple sclerosis","volume":"10","author":"Varhaug","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2024.105748_bib0062","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1002\/acn3.51676","article-title":"Age- and disease-specific reference values for neurofilament light presented in an online interactive support interface","volume":"9","author":"Vermunt","year":"2022","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.msard.2024.105748_bib0063","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1007\/s00415-020-09917-x","article-title":"Neurofilaments in progressive multiple sclerosis: a systematic review","volume":"268","author":"Williams","year":"2021","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2024.105748_bib0064","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S1474-4422(22)00469-0","article-title":"Time to reconsider the classification of multiple sclerosis","volume":"22","author":"Yamamura","year":"2023","journal-title":"Lancet Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824003250?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824003250?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T10:29:14Z","timestamp":1778840954000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034824003250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":64,"alternative-id":["S2211034824003250"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2024.105748","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence of elevated sNFL in a real-world setting: Results on 908 patients with different multiple sclerosis types and treatment conditions","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2024.105748","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105748"}}